Celltech's Flexible Dealmaking
Celltech's recent research, development and marketing deals with Biogen and Amgen are innovatively flexible, and, combined with a smooth transition in top management at Celltech, may just be the best way to refocus investor attention--distracted by questionable marketing ventures--on the UK company's R&D expertise and late-stage pipeline.
You may also be interested in...
Europe presents a big opportunity--but also significant challenges--to niche players seeking to expand. Some firms--such as US group Cephalon--have bought big in Europe, others like Shire and Celltech have made do with smaller acquisitions onto which they hope to build their own tailored infrastructure. No single approach is the same, and none has yet proven a clear winner. But all depend on finding the right products.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.